What Galecto does

Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biopharmaceutical company developing therapeutics for hematological cancers, headquartered in Boston, Massachusetts, and incorporated in Delaware with a pending redomestication to the Cayman Islands. The company was founded in 2011 and operates a portfolio anchored by two investigational assets: DMR-001, a monoclonal antibody targeting mutant calreticulin (mutCALR) for myeloproliferative neoplasms including essential thrombocythemia and myelofibrosis, which was acquired in November 2025 through the purchase of Damora Therapeutics and uses a proprietary half-life extension technology to enable subcutaneous administration; and GB3226, a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML). Galecto plans to file a regulatory submission for DMR-001 in mid-2026 to initiate a global Phase 1/1b trial, with two clinical proof-of-concept datasets expected beginning in mid-2027.

Galecto is pre-revenue and has no commercialized products, generating no product sales, royalties, or collaboration revenue as of the latest disclosures. Its business model is conventional clinical-stage biotech: advance candidates through IND-enabling work and clinical trials with the intent to either commercialize independently in rare-disease indications or partner for larger indications, monetizing ultimately through drug sales rather than software, services, or licensing fees today. The company's go-to-market relies on scientific communication channels — primarily presentations at major hematology/oncology conferences such as ASH — and investor relations, with planned post-approval distribution through specialty and hospital pharmacies typical for rare-disease therapeutics.

The company raised approximately $284.9 million in a November 2025 oversubscribed private placement concurrent with the Damora acquisition, followed by a $275 million underwritten public offering in February 2026, providing stated runway into 2029. Capital structure and shareholder base include specialist biotech investors (Fairmount, RA Capital, Perceptive Advisors, Janus Henderson, Viking Global, Wellington, BB Biotech, Forbion, OrbiMed, Novo Holdings), and Leerink Partners initiated coverage with an Outperform rating and a $46 price target, modeling peak sales of $3.3 billion for DMR-001 in myelofibrosis and $3.0 billion in essential thrombocythemia. Leadership transitioned in early 2026, with founder/CEO Hans T. Schambye departing and former Blueprint Medicines executive Sherwin Sattarzadeh appointed interim principal executive officer.

Name

Galecto

Legal name

Galecto, Inc.

Website

https://galecto.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Hematological Cancer Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industry

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

Keywords

• Clinical-stage biopharmaceutical
• Monoclonal antibody therapy
• Hematological cancer therapeutics
• Myeloproliferative neoplasm drugs
• Fibrosis therapeutics

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Marketing channels1 record

Core offering

Galecto is a clinical-stage biopharmaceutical company developing novel disease-modifying treatments for hematological cancers. Its lead candidate DMR-001 is an investigational monoclonal antibody therapy targeting mutant calreticulin-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), while GB3226 is a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia. The company does not yet have commercialized products and intends to commercialize these candidates through specialty pharmaceutical distribution channels upon regulatory approval.

Product overview

Galecto is a clinical-stage biopharmaceutical company developing treatments for hematological cancers. The company operates a portfolio approach with two key investigational candidates: DMR-001 (acquired through Damora Therapeutics), a monoclonal antibody therapy targeting mutant calreticulin-driven myeloproliferative neoplasms, and GB3226, a dual inhibitor for acute myeloid leukemia.

Differentiator

Problem solved

Functional benefit

Products and services

• DMR-001 An investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR) with best-in-class potential for treating myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). Designed to exclusively bind mutCALR with exquisite selectivity, potency, and extended half-life, enabling convenient infrequent subcutaneous dosing via autoinjector. Preclinical studies demonstrated approximately 10-fold increase in potency against Type 2 mutant cells and approximately 5-fold increase in half-life versus reference antibody.
• GB3226 A dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML). Novel mechanism targeting both ENL-YEATS and FLT3 pathways, demonstrating potent preclinical activity and promising efficacy in AML models across various genotypes. Designed for the treatment of acute myeloid leukemia patients across heterogeneous genetic subsets.

Quantifiable outcome

• Approximately 10-fold increase in potency against Type 2 mutant cells compared to reference antibody
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Damora TherapeuticscoreStrategic or Co-development Partner · 10 November 2025Galecto acquired Damora Therapeutics, a biotech company focused on therapies for mutant calreticulin-driven myeloproliferative neoplasms. The acquisition enhances Galecto's pipeline for hematological cancers and was supported by a private placement of approximately $285 million.
• Paragon TherapeuticscoreTechnology or IntegrationGalecto issued a warrant to Paragon Therapeutics' affiliate Paramora Holding LLC for the purchase of up to 628,302 shares at $23.01 per share, as part of an antibody discovery and option agreement. This partnership supports Galecto's antibody discovery programs.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cogent Biosciences: Clinical-stage biotech developing bezuclastinib and other kinase inhibitors for systemic mastocytosis and mutant KIT-driven myeloid neoplasms, directly competing with Galecto in the MPN / hematologic malignancy space with similar stage and modality profile.
• Disc Medicine: Clinical-stage rare hematology biotech developing therapeutics for hematologic disorders including myelofibrosis and other bone marrow failure diseases, comparable in size, stage, and therapeutic area focus to Galecto's mutCALR-driven MPN franchise.
• Blueprint Medicines: Commercial-stage rare hematology/oncology company with AYVAKIT (avapritinib) in systemic mastocytosis and GAVRETO in lung cancer. Highly comparable for its MPN-adjacent positioning, leadership pedigree (Galecto's COO and CMO are alumni), and rare-disease strategy.

Broad incumbents

• Bristol-Myers Squibb: Major pharma with an established MPN franchise including Reblozyl (luspatercept) and Inrebic (fedratinib) for myelofibrosis. Represents the incumbent standard of care and likely strategic acquirer for next-generation MPN assets like DMR-001.
• Incyte: Developer and marketer of Jakafi (ruxolitinib), the leading JAK inhibitor for myelofibrosis and polycythemia vera. Sets the commercial benchmark against which any new MPN therapy, including DMR-001, will be measured.
• GSK: Marketer of Ojjaara (momelotinib) for myelofibrosis patients with anemia, acquired through Sierra Oncology. Directly competes with Galecto's potential myelofibrosis positioning of DMR-001.
• Sobi (Swedish Orphan Biovitrum): Acquired CTI BioPharma and markets Vonjo (pacritinib) for myelofibrosis. A key established player in the MPN space and a credible strategic acquirer profile similar to the types of companies Galecto could eventually partner with.
• AbbVie: Major oncology player with a hematology presence and historically active in MPN commercial landscapes (e.g., Imbruvica, Venclexta). Represents a likely large-pharma counterparty for partnership or acquisition of a focused MPN asset like DMR-001.

Emerging players

• Keros Therapeutics: Clinical-stage biotech developing therapeutics targeting TGF-beta superfamily for hematologic disorders including MDS and MPNs. Comparable in stage and rare hematology focus, though with a different mechanistic approach.
• Geron Corporation: Recently launched Rytelo (imetelstat) for transfusion-dependent MDS, with ongoing development in myelofibrosis. Comparable as a late clinical / early commercial rare hematology company pursuing MPN indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galecto